hrcak mascot   Srce   HID

Stručni rad

CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience

Ernest Bilić ; University of Zagreb, School of Medicine, Zagreb, Croatia
Ranka Femenić ; University Hospital Center Zagreb, Zagreb, Croatia
Josip Konja ; University of Zagreb, School of Medicine, Zagreb, Croatia
Marija Šimat ; University Hospital Center Zagreb, Zagreb, Croatia
Klara Dubravčić ; University Hospital Center Zagreb, Zagreb, Croatia
Drago Batinić ; University of Zagreb, School of Medicine, Zagreb, Croatia
Sunčica Ries ; University of Applied Health Studies, Zagreb, Croatia
Ljubica Rajić ; University of Zagreb, School of Medicine, Zagreb, Croatia

Puni tekst: engleski, pdf (137 KB) str. 171-175 preuzimanja: 1.227* citiraj
APA 6th Edition
Bilić, E., Femenić, R., Konja, J., Šimat, M., Dubravčić, K., Batinić, D., ... Rajić, Lj. (2010). CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience. Collegium antropologicum, 34 (1), 171-175. Preuzeto s https://hrcak.srce.hr/51259
MLA 8th Edition
Bilić, Ernest, et al. "CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience." Collegium antropologicum, vol. 34, br. 1, 2010, str. 171-175. https://hrcak.srce.hr/51259. Citirano 26.07.2021.
Chicago 17th Edition
Bilić, Ernest, Ranka Femenić, Josip Konja, Marija Šimat, Klara Dubravčić, Drago Batinić, Sunčica Ries i Ljubica Rajić. "CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience." Collegium antropologicum 34, br. 1 (2010): 171-175. https://hrcak.srce.hr/51259
Harvard
Bilić, E., et al. (2010). 'CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience', Collegium antropologicum, 34(1), str. 171-175. Preuzeto s: https://hrcak.srce.hr/51259 (Datum pristupa: 26.07.2021.)
Vancouver
Bilić E, Femenić R, Konja J, Šimat M, Dubravčić K, Batinić D i sur. CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience. Collegium antropologicum [Internet]. 2010 [pristupljeno 26.07.2021.];34(1):171-175. Dostupno na: https://hrcak.srce.hr/51259
IEEE
E. Bilić, et al., "CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience", Collegium antropologicum, vol.34, br. 1, str. 171-175, 2010. [Online]. Dostupno na: https://hrcak.srce.hr/51259. [Citirano: 26.07.2021.]

Sažetak
Lymphomas represent the third most common group of cancers in childhood and adolescence, mature B non Hodgkin’s lymphoma (B-NHL) accounting for up to 60% of newly diagnosed patients. The diagnosis of specific entities of B-NHL is based on well-defined morphologic analysis, immunophenotyping, cytogenetics and molecular genetics, which determine the optimal treatment strategy. In adult population a major turning point in treatment of B-NHL has been achieved since rituximab, in combination with CHOP has improved the survival rate up to 19%. Rituximab is a chimeric monoclonal antibody that targets CD20, a transmembrane calcium channel expressed on normal and malignant B-cells that mediates cytotoxic, apoptotic and anti-proliferative effects. The effect of rituximab in pediatric population is still not well enough investigated. Based on morphology and immunophenotype of malignant cells, seven children with B-NHL in our institution were eligible for treatment with modified B-NHL-Berlin-Frankfurt-Münster (BFM)-95-based protocol with rituximab administered on day -5. The complete remission was achieved in all seven patients. Six patients are still in complete remission at least 12 months after having finished chemotherapy and one patient relapsed two months after the last cycle and subsequently died. Major adverse effects observed during treatment were prolonged B-cell depletion and myelosupression. Rituximab in combination with B-NHL-BFM-95 protocol was otherwise well tolerated and proved to be effective in children and adolescents with B-NHL. The number of our patients is too small and the follow-up of a larger group of patients will help in defining the role of rituximab in the treatment of childhood B-NHL.

Ključne riječi
non Hodgkin lymphoma; children; rituximab

Hrčak ID: 51259

URI
https://hrcak.srce.hr/51259

Posjeta: 1.583 *